
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="1525516F8AF4327305516F001CC9E41B.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="scirep">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Scientific Reports">
<meta name="citation_title" content="Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy">
<meta name="citation_author" content="Anthony E Peters">
<meta name="citation_author_institution" content="Division of Cardiology, Duke University School of Medicine, Durham, NC USA">
<meta name="citation_author_institution" content="Duke Clinical Research Institute, Durham, NC USA">
<meta name="citation_author" content="Maggie Nguyen">
<meta name="citation_author_institution" content="Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N. Duke Street, Durham, NC 27710 USA">
<meta name="citation_author" content="Jennifer B Green">
<meta name="citation_author_institution" content="Duke Clinical Research Institute, Durham, NC USA">
<meta name="citation_author_institution" content="Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC USA">
<meta name="citation_author" content="Ewan R Pearson">
<meta name="citation_author_institution" content="Division of Population Health and Genomics, University of Dundee, Dundee, Scotland, UK">
<meta name="citation_author" content="John B Buse">
<meta name="citation_author_institution" content="Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC USA">
<meta name="citation_author" content="Harald Sourij">
<meta name="citation_author_institution" content="Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria">
<meta name="citation_author" content="Adrian F Hernandez">
<meta name="citation_author_institution" content="Division of Cardiology, Duke University School of Medicine, Durham, NC USA">
<meta name="citation_author_institution" content="Duke Clinical Research Institute, Durham, NC USA">
<meta name="citation_author" content="Naveed Sattar">
<meta name="citation_author_institution" content="Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK">
<meta name="citation_author" content="Rury R Holman">
<meta name="citation_author_institution" content="Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK">
<meta name="citation_author" content="Robert J Mentz">
<meta name="citation_author_institution" content="Division of Cardiology, Duke University School of Medicine, Durham, NC USA">
<meta name="citation_author_institution" content="Duke Clinical Research Institute, Durham, NC USA">
<meta name="citation_author" content="Svati H Shah">
<meta name="citation_author_institution" content="Division of Cardiology, Duke University School of Medicine, Durham, NC USA">
<meta name="citation_author_institution" content="Duke Clinical Research Institute, Durham, NC USA">
<meta name="citation_author_institution" content="Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N. Duke Street, Durham, NC 27710 USA">
<meta name="citation_publication_date" content="2025 Aug 18">
<meta name="citation_volume" content="15">
<meta name="citation_firstpage" content="30170">
<meta name="citation_doi" content="10.1038/s41598-025-14414-0">
<meta name="citation_pmid" content="40825966">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/pdf/41598_2025_Article_14414.pdf">
<meta name="description" content="Ejection fraction (EF) is a key component of heart failure (HF) classification. However, the biologic basis of HF with mildly reduced EF (HFmrEF) as a distinct biologic entity distinct from HF with preserved EF (HFpEF) and reduced EF (HFrEF) has not ...">
<meta name="og:title" content="Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Ejection fraction (EF) is a key component of heart failure (HF) classification. However, the biologic basis of HF with mildly reduced EF (HFmrEF) as a distinct biologic entity distinct from HF with preserved EF (HFpEF) and reduced EF (HFrEF) has not ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Searchâ€¦
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12361379">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41598-025-14414-0"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41598_2025_Article_14414.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12361379%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12361379/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12361379/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-scirep.jpg" alt="Scientific Reports logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Scientific Reports" title="Link to Scientific Reports" shape="default" href="http://www.nature.com/srep" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sci Rep</button></div>. 2025 Aug 18;15:30170. doi: <a href="https://doi.org/10.1038/s41598-025-14414-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41598-025-14414-0</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci%20Rep%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci%20Rep%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Peters%20AE%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Anthony E Peters</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Anthony E Peters</span></h3>
<div class="p">
<sup>1</sup>Division of Cardiology, Duke University School of Medicine, Durham, NC USA </div>
<div class="p">
<sup>2</sup>Duke Clinical Research Institute, Durham, NC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Peters%20AE%22%5BAuthor%5D" class="usa-link"><span class="name western">Anthony E Peters</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nguyen%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Maggie Nguyen</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Maggie Nguyen</span></h3>
<div class="p">
<sup>3</sup>Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N. Duke Street, Durham, NC 27710 USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nguyen%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maggie Nguyen</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Green%20JB%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Jennifer B Green</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Jennifer B Green</span></h3>
<div class="p">
<sup>2</sup>Duke Clinical Research Institute, Durham, NC USA </div>
<div class="p">
<sup>4</sup>Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Green%20JB%22%5BAuthor%5D" class="usa-link"><span class="name western">Jennifer B Green</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pearson%20ER%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Ewan R Pearson</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Ewan R Pearson</span></h3>
<div class="p">
<sup>5</sup>Division of Population Health and Genomics, University of Dundee, Dundee, Scotland, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pearson%20ER%22%5BAuthor%5D" class="usa-link"><span class="name western">Ewan R Pearson</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Buse%20JB%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">John B Buse</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">John B Buse</span></h3>
<div class="p">
<sup>6</sup>Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Buse%20JB%22%5BAuthor%5D" class="usa-link"><span class="name western">John B Buse</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sourij%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Harald Sourij</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Harald Sourij</span></h3>
<div class="p">
<sup>7</sup>Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sourij%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Harald Sourij</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hernandez%20AF%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Adrian F Hernandez</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Adrian F Hernandez</span></h3>
<div class="p">
<sup>1</sup>Division of Cardiology, Duke University School of Medicine, Durham, NC USA </div>
<div class="p">
<sup>2</sup>Duke Clinical Research Institute, Durham, NC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hernandez%20AF%22%5BAuthor%5D" class="usa-link"><span class="name western">Adrian F Hernandez</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sattar%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Naveed Sattar</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Naveed Sattar</span></h3>
<div class="p">
<sup>8</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sattar%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Naveed Sattar</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Holman%20RR%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Rury R Holman</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Rury R Holman</span></h3>
<div class="p">
<sup>9</sup>Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Holman%20RR%22%5BAuthor%5D" class="usa-link"><span class="name western">Rury R Holman</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mentz%20RJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Robert J Mentz</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Robert J Mentz</span></h3>
<div class="p">
<sup>1</sup>Division of Cardiology, Duke University School of Medicine, Durham, NC USA </div>
<div class="p">
<sup>2</sup>Duke Clinical Research Institute, Durham, NC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mentz%20RJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Robert J Mentz</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shah%20SH%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Svati H Shah</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Svati H Shah</span></h3>
<div class="p">
<sup>1</sup>Division of Cardiology, Duke University School of Medicine, Durham, NC USA </div>
<div class="p">
<sup>2</sup>Duke Clinical Research Institute, Durham, NC USA </div>
<div class="p">
<sup>3</sup>Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N. Duke Street, Durham, NC 27710 USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shah%20SH%22%5BAuthor%5D" class="usa-link"><span class="name western">Svati H Shah</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>âœ‰</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Division of Cardiology, Duke University School of Medicine, Durham, NC USA </div>
<div id="Aff2">
<sup>2</sup>Duke Clinical Research Institute, Durham, NC USA </div>
<div id="Aff3">
<sup>3</sup>Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N. Duke Street, Durham, NC 27710 USA </div>
<div id="Aff4">
<sup>4</sup>Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC USA </div>
<div id="Aff5">
<sup>5</sup>Division of Population Health and Genomics, University of Dundee, Dundee, Scotland, UK </div>
<div id="Aff6">
<sup>6</sup>Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC USA </div>
<div id="Aff7">
<sup>7</sup>Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria </div>
<div id="Aff8">
<sup>8</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK </div>
<div id="Aff9">
<sup>9</sup>Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>âœ‰</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 4; Accepted 2025 Jul 30; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Â© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the articleâ€™s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articleâ€™s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12361379Â Â PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40825966/" class="usa-link">40825966</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>
<strong>Previous version available:</strong> This article is based on a previously available preprint posted on medRxiv on May 16, 2023: "<a href="/articles/PMC10246051/" class="usa-link">
Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy
</a>".</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Ejection fraction (EF) is a key component of heart failure (HF) classification. However, the biologic basis of HF with mildly reduced EF (HFmrEF) as a distinct biologic entity distinct from HF with preserved EF (HFpEF) and reduced EF (HFrEF) has not been well characterized. The EXSCEL trial randomized participants with type 2 diabetes (T2DM) to a once-weekly glucagon-like peptide receptor agonist (GLP-1 RA) exenatide (EQW) vs. placebo. For this study, profiling of ~â€‰5000 proteins using the SomaLogic SomaScan platform was performed in baseline and 12-month serum samples from <em>N</em>â€‰=â€‰1199 participants with prevalent HF at baseline. Unsupervised principal component analysis (PCA) and ANOVA (FDR <em>p</em>â€‰&lt;â€‰0.1) were used to identify proteins that were significantly between three EF groups (EFâ€‰&gt;â€‰55% [HFpEF], EF 40â€“55% [HFmrEF], EFâ€‰&lt;â€‰40% [HFrEF], categories as previously curated in the parent trial). Cox proportional hazards was used to assess association between baseline levels of proteins significantly different between groups, and changes in protein level between baseline and 12-month, with time-to-HF hospitalization. Mixed models were used to assess whether significant proteins changed differentially with exenatide vs. placebo therapy. Of <em>N</em>â€‰=â€‰1199 EXSCEL participants with prevalent HF, 284 (24%), 704 (59%) and 211 (18%) had HFpEF, HFmrEF and HFrEF, respectively. Eight principal components analysis (PCA) protein factors differed significantly across the three EF groups, of which 270 individual proteins within those factors were significant. The majority of proteins (75%) demonstrated similar levels in HFmrEF and HFpEF with higher levels in HFrEF. Biologic pathways of epithelial-mesenchymal transition, ECM receptor interaction (tenascin C [TNC], COL28A1), complement and coagulation cascades, and epithelial apical surface and junctions demonstrated enrichment among proteins with this dominant pattern. A minority of proteins (1%) demonstrated similar levels between HFmrEF and HFrEF with lower levels in HFpEF, including MMP-9 (<em>p</em>â€‰&lt;â€‰0.0001). Baseline levels of the majority of the 270 proteins (92%) were also associated with time-to-incident HF hospitalization including domains of extracellular matrix (COL28A1, TNC), angiogenesis (VEGFa, VEGFd), myocyte stretch (NT-proBNP), and renal function (cystatin-C). Change in levels of 8% of these from baseline to 12 months (including increase in TNC) predicted incident HF hospitalization (<em>p</em>â€‰&lt;â€‰0.05). Levels of 41% of the 270 significant proteins (including TNC and NT-proBNP; <em>p</em>â€‰&lt;â€‰0.0001) were reduced differentially by EQW compared with placebo. In conclusion, we found that serum levels of the vast majority of proteins across multiple biologic domains were similar between HFmrEF and HFpEF suggesting that HFmrEF may be more biologically similar to HFpEF than HFrEF. We also identified specific biomarkers showing this pattern, most notably TNC, for which baseline and change levels predicted incident HF hospitalization and were beneficially modified by the GLP-1 RA EQW. These results may offer unique data on prognosis and pharmacotherapy modification with variability by EF.</p>
<section id="sec1"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1038/s41598-025-14414-0.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Subject terms:</strong> Cardiovascular biology, Cell biology, Molecular biology, Cardiac hypertrophy</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par3">Left ventricular ejection fraction (LVEF) categories, now including HF with mildly reduced EF (HFmrEF), are a key component of classifying patients with heart failure (HF) and guiding implementation of therapies<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup>. Yet, the biologic basis of HFmrEF as an entity distinct from HF with preserved EF (HFpEF) and HF with reduced EF (HFrEF) has not been well characterized. There is accumulating evidence for different biological signatures underlying HFpEF as compared with HFrEF<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>â€“<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup> but HFmrEF remains a less well-defined entity. Data on HFmrEF as comprising a distinct pathophysiology or representing simply a transition between HFrEF and HFpEF are mixed<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a></sup>. Prior data has suggested that HFmrEF has some similarities to HFrEF with regards to HF etiology (e.g. more commonly ischemic), outcomes, and response to therapy<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>â€“<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup> although these data are inconsistent with some recent studies indicating more clinical similarities between HFpEF and HFmrEF<sup><a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup>.</p>
<p id="Par4">Molecular profiling can help evaluate the underlying biological basis of disease while simultaneously identifying clinically relevant biomarkers. Notably, proteomics studies including HFmrEF have shown unique, intermediary signatures in HFmrEF, but have been limited by small sample sizes, focus on a smaller set of proteins, and/or lack of longitudinal biomarker data<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>,<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>,<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>. At a clinical level, there is an increasing movement to advance beyond LVEF in phenotyping patients with HF due the limited relationship between LVEF and pathophysiology, outcomes, and treatment response<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>â€“<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup>. An improved understanding of the biological correlates of LVEF phenotypes and related biomarkers in HF could inform patient classification and management. Thus, to address these interconnected gaps in the literature, we used proteomics applied to a large clinical trial database to define molecular processes across the EF spectrum in HF and investigated their role as prognostic biomarkers of incident hospitalization for HF (hHF) outcomes.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec20"><h3 class="pmc_sec_title">Study population</h3>
<p id="Par5">The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) evaluated the effects of once-weekly exenatide (EQW) in adults with type 2 diabetes mellitus (T2DM). Design, baseline characteristics, and primary results have been published<sup><a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>â€“<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a></sup>. The EXSCEL study population was enriched for participants with history of prior CV events including previous coronary, cerebrovascular, or peripheral vascular events or stenosis and also included a primary prevention group<sup><a href="#CR20" class="usa-link" aria-describedby="CR20">20</a></sup>. Biospecimens were collected at enrollment in a subset of EXSCEL participants (<em>N</em>â€‰=â€‰5668, 38.4% of the overall trial population).</p>
<p id="Par6">For this study, the subset of participants with a history of HF at baseline (i.e. prevalent HF) who had consented for and had biospecimens collected were included. Presence or absence of history of clinical HF was captured upon enrollment into the trial. Clinical HF status at baseline was prospectively recorded by the clinician-investigator based on all available clinical data including patientsâ€™ signs/symptoms and objective measures such as echocardiography and biomarker data (e.g., natriuretic peptide levels)<sup><a href="#CR22" class="usa-link" aria-describedby="CR22">22</a></sup>. Participants with prevalent HF were further stratified across three EF groups as defined and curated in the parent EXSCEL trial as follows: preserved ejection fraction (HFpEF, EFâ€‰&gt;â€‰55%), mildly reduced ejection fraction (HFmrEF, EF 40â€“55%), and reduced ejection fraction (HFrEF, EFâ€‰&lt;â€‰40%). Incident HF events were defined as any heart failure hospitalization (hHF) as the primary reason for hospitalization. A blinded, independent clinical events classification committee adjudicated all the components of the primary composite and secondary outcomes including hHF.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Proteomic profiling</h3>
<p id="Par7">Profiling of ~â€‰5000 proteins was performed in frozen serum (not previously thawed) collected at baseline (enrollment) and at 12Â month follow-up. Profiling was performed utilizing the SomaScan assay (SomaLogic Inc., Boulder, USA). The design and performance characteristics of this assay have been previously described<sup><a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>,<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a></sup>. This assay uses DNA-based binding reagents (modified aptamers) to quantify, with high specificity, the availability of binding epitopes on plasma proteins<sup><a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>,<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup> enabling high throughput relative quantification of thousands of proteins in small amounts of sample. Samples were run in three dilutions to ensure dynamic range in serum. Eleven control replicates from three control lots were included in each 96-sample plate and five calibrator replicates per run were used with a reference standard. Three quality control (QC) replicates were also included per run with a reference standard to evaluate the accuracy of the assay after data standardization. Prior studies have established the specificity of the majority of the SomaScan reagents using affinity-capture experiments and orthogonal means (i.e., presence of <em>cis</em> genetic variants and validation by mass spectrometry)<sup><a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>,<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>.</p></section><section id="Sec22"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par8">Proteomics data first underwent QC procedures and standard normalization<sup><a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup> using adaptive median normalization by maximum likelihood, scaling the total fluorescence from the experimental sample based on point and variance estimates from a population control set as previously done. This procedure identified 5.1% of samples for having normalization scale factors outside recommended ranges and were removed from analysis. Unsupervised principal component analysis (PCA) with varimax rotation was performed on 4979 proteins (baseline samples) passing QC measures as a means of dimensionality reduction to reduce the burden of multiple comparisons and identify potential shared biologic pathways. Before PCA, to address considerations of skewness without compromising sample size and maintain relative rankings, individual protein outlier values (defined as being +/âˆ’ 6 median absolute deviation beyond the median value for the entire cohort for that protein) were k nearest neighbor imputed (kâ€‰=â€‰10 (package impute from BioConductor). Across all individual protein levels at both time points for this study (baseline <em>n</em>â€‰=â€‰10311509, follow-up <em>n</em>â€‰=â€‰109792; 1%) were considered outliers and were knn imputed. All protein values were log-transformed after imputation and prior to inclusion in PCA. To calculate factor scores, baseline samples were scaled and these mean/ scales were used to scale follow up samples. The Kaiser criterion (eigenvalueâ€‰&gt;â€‰1) was used to identify PCA protein factors for inclusion in analysis. Each PCA factor is a weighted sum of all proteins for each participant. Proteins with an absolute value factor loadâ€‰â‰¥â€‰0.4 were considered as heavily loaded and thus composing a given factor and were analyzed as individual proteins for significant PCA factors. PCA factors with only one protein heavily loaded in a given factor were not analyzed as a factor but instead as the individual heavily loaded protein.</p>
<p id="Par9">For discovery analyses, ANOVA was used to determine differences in PCA protein factor levels across the three EF groups (HFpEF, HFmrEF and HFrEF) and adjusted for multiple comparisons using the Benjamini Hochberg false discovery rate [FDR] <em>p</em>â€‰&lt;â€‰0.1 at level of factors (Supplemental Fig.Â <a href="#MOESM2" class="usa-link">1</a>). Individual proteins heavily loaded on PCA factors significant from the ANOVA were then analyzed in subsequent sensitivity analyses (nominal significance i.e. <em>p</em>â€‰&lt;â€‰0.05) as follows: (1) ANOVA across EF groups; (2) of proteins significant in ANOVA, unadjusted pairwise comparisons using t-tests with pooled SD between the three EF groups; (3) significant individual proteins were then assessed in pairwise multivariable model adjusted for age, sex, race, hypertension, hyperlipidemia, obesity by enrollment body mass index (BMIâ€‰â‰¥â€‰30Â kg/m<sup>2</sup>), and enrollment hemoglobin A1C; (4) Cox proportional hazard models were constructed to assess for relationship between baseline protein and change in protein level (baseline to 12Â month; adjusting for baseline protein level) with time-to-incident hHF; for proteins violating the proportional hazards assumption, a parametric accelerated failure time (AFT) model was constructed for comparison; the hazard ratio (HR) was calculated by a one unit increase in the log-transformed protein level; adjusted HR (aHR) calculated with same adjustment variables from above analysis #3; and (5) the effect of EQW on protein levels was assessed using linear mixed effects models inclusive of terms for treatment arm (EQW vs. placebo), protein timepoint (baseline, 12 months) and an interaction term (treatment*timepoint). For incident HF hospitalization analysis with change in protein level over time, only events occurring after 12-month follow-up were included.</p>
<p id="Par10">Based on results from pairwise multivariable models (sensitivity analysis #3), individual proteins were classified into patterns for being similar or discordant between EF groups (i.e. based on nominal p-value, proteins not significantly different between two EF groups were considered similar between those groups; proteins significantly different between two EF groups were considered discordant) and by whether protein levels were significantly higher/lower in one EF group (or increasing/decreasing significantly across groups).</p>
<p id="Par11">Overrepresentation analysis (ORA) using the Molecular Signatures Database (MSigDB) was performed to highlight biologic pathways enriched among individual proteins, starting with those with multivariable ANOVA <em>p</em>-valueâ€‰&lt;â€‰0.05 among EF groups, and narrowing to those with (1) similar levels in HFmrEF and HFpEF (multivariable pairwise <em>p</em>-valueâ€‰â‰¥â€‰0.05) and, separately, (2) similar levels in HFmrEF and HFrEF (multivariable pairwise <em>p</em>-valueâ€‰â‰¥â€‰0.05). ORA was conducted using a hypergeometric test of these specific proteins on a background of all tested proteins. A pathway was considered significantly enriched if its nominal <em>p</em>-valueâ€‰&lt;â€‰0.05. Two gene collections (Hallmark [50 gene sets] and Canonical Pathways derived from the KEGG pathway database [CP: KEGG; 186 gene sets]) were utilized<sup><a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>. Primary biological domains (i.e. extracellular matrix/space regulation, endothelial-mesenchymal transition, angiogenesis, etc.) for this analysis were defined by presence in a combination of multiple sources including â€˜Biological Processesâ€™ and Cellular Componentsâ€™ of Gene Ontology, biological pathways defined by the Molecular Signatures Database (MSigDB), and several HF-biomarker literature sources<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>â€“<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a></sup>.</p>
<p id="Par12">All methods were carried out in accordance with relevant guidelines and regulations. The EXSCEL study protocol was approved by the ethics committee at each participating site, as described in the primary trial manuscript<sup><a href="#CR21" class="usa-link" aria-describedby="CR21">21</a></sup>. All patients provided written informed consent in the parent study and for use of their stored biospecimens for future use.</p></section></section><section id="Sec6"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec7"><h3 class="pmc_sec_title">Baseline characteristics and differences between EF groups</h3>
<p id="Par13">Among EXSCEL participants with available biospecimens (<em>N</em>â€‰=â€‰5668, 38.4% of total EXSCEL population), <em>N</em>â€‰=â€‰1199 (21.2%) of individuals had prevalent HF (Supplemental Table <a href="#MOESM2" class="usa-link">1</a>). There were slight differences in the included cohort as compared to other participants from EXSCEL not included including slightly higher age, higher percentage of male sex and Caucasian race, a higher burden of cardiovascular disease and cardiovascular medical therapy. Of these, <em>N</em>â€‰=â€‰284 (24%) had HFpEF, <em>N</em>â€‰=â€‰704 (59%) had HFmrEF, and <em>N</em>â€‰=â€‰211 (18%) had HFrEF. Baseline characteristics of the study population overall and by EF group are included in TableÂ <a href="#Tab1" class="usa-link">1</a>. Baseline medications of participants by EF group are included in Supplemental Table <a href="#MOESM2" class="usa-link">2</a>. Participants with HFmrEF had an overall intermediate demographic and clinical profile compared with participants with HFrEF or HFpEF as follows: participants with HFmrEF were 71% male (compared with 78% of HFrEF and 64% of HFpEF), 90% white (vs. 83% of HFrEF and 95% of HFpEF), and 66% enrolled in Europe (vs. 47% for HFrEF and 82% for HFpEF). Participants with HFmrEF were 41% non-smokers (vs. 60% of HFpEF and 38% of HFrEF) and had an intermediate burden of prior cardiovascular events and coronary disease at baseline, compared to participants with HFrEF or HFpEF (TableÂ <a href="#Tab1" class="usa-link">1</a>). Participants with HFrEF demonstrated higher rates of HF hospitalization, cardiovascular mortality, and all-cause mortality, compared with those with HFmrEF or HFpEF (Supplemental Table <a href="#MOESM2" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline characteristics of participants by ejection fraction group.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">HFpEF (<em>n</em>â€‰=â€‰284)</th>
<th align="left" colspan="1" rowspan="1">HFmrEF (<em>n</em>â€‰=â€‰704)</th>
<th align="left" colspan="1" rowspan="1">HFrEF (<em>n</em>â€‰=â€‰211)</th>
<th align="left" colspan="1" rowspan="1">
<em>p</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Age</td>
<td align="center" colspan="1" rowspan="1">64.0 (8.9)</td>
<td align="center" colspan="1" rowspan="1">62.6 (9.1)</td>
<td align="center" colspan="1" rowspan="1">64.0 (9.5)</td>
<td align="center" colspan="1" rowspan="1">0.05</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male sex</td>
<td align="center" colspan="1" rowspan="1">181 (63.7)</td>
<td align="center" colspan="1" rowspan="1">500 (71.0)</td>
<td align="center" colspan="1" rowspan="1">164 (77.7)</td>
<td align="center" colspan="1" rowspan="1">0.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Self-reported race</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">White</td>
<td align="center" colspan="1" rowspan="1">274 (96.5%)</td>
<td align="center" colspan="1" rowspan="1">630 (89.5)</td>
<td align="center" colspan="1" rowspan="1">175 (82.9%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Black</td>
<td align="center" colspan="1" rowspan="1">4 (1.4%)</td>
<td align="center" colspan="1" rowspan="1">12 (1.7%)</td>
<td align="center" colspan="1" rowspan="1">7 (3.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asian</td>
<td align="center" colspan="1" rowspan="1">5 (1.8%)</td>
<td align="center" colspan="1" rowspan="1">26 (3.7)</td>
<td align="center" colspan="1" rowspan="1">12 (5.7%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hispanic</td>
<td align="center" colspan="1" rowspan="1">1 (0.4%)</td>
<td align="center" colspan="1" rowspan="1">31 (4.4%)</td>
<td align="center" colspan="1" rowspan="1">16 (7.6%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Indian (American) or Alaska Native</td>
<td align="center" colspan="1" rowspan="1">0 (0.0%)</td>
<td align="center" colspan="1" rowspan="1">3 (0.4%)</td>
<td align="center" colspan="1" rowspan="1">1 (0.5%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Native Hawaiian or Other Pacific Islander</td>
<td align="center" colspan="1" rowspan="1">0 (0.0%)</td>
<td align="center" colspan="1" rowspan="1">2 (0.3%)</td>
<td align="center" colspan="1" rowspan="1">0 (0.0%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Region</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asia Pacific</td>
<td align="center" colspan="1" rowspan="1">7 (2.5%)</td>
<td align="center" colspan="1" rowspan="1">28 (4.0%)</td>
<td align="center" colspan="1" rowspan="1">12 (5.7%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Europe</td>
<td align="center" colspan="1" rowspan="1">234 (82.4%)</td>
<td align="center" colspan="1" rowspan="1">466 (66.2%)</td>
<td align="center" colspan="1" rowspan="1">99 (46.9%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Latin America</td>
<td align="center" colspan="1" rowspan="1">0 (0.0%)</td>
<td align="center" colspan="1" rowspan="1">20 (2.8%)</td>
<td align="center" colspan="1" rowspan="1">17 (8.1%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">North America</td>
<td align="center" colspan="1" rowspan="1">43 (15.1%)</td>
<td align="center" colspan="1" rowspan="1">190 (27.0%)</td>
<td align="center" colspan="1" rowspan="1">83 (39.3%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Smoking status</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Current</td>
<td align="center" colspan="1" rowspan="1">26 (9.2%)</td>
<td align="center" colspan="1" rowspan="1">86 (12.2%)</td>
<td align="center" colspan="1" rowspan="1">21 (10.0%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Former</td>
<td align="center" colspan="1" rowspan="1">88 (31.0%)</td>
<td align="center" colspan="1" rowspan="1">327 (46.4%)</td>
<td align="center" colspan="1" rowspan="1">109 (51.7%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Never</td>
<td align="center" colspan="1" rowspan="1">170 (59.9%)</td>
<td align="center" colspan="1" rowspan="1">291 (41.3%)</td>
<td align="center" colspan="1" rowspan="1">81 (38.4%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Medical history at baseline</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prior cardiovascular event at randomization</td>
<td align="center" colspan="1" rowspan="1">234 (82.4%)</td>
<td align="center" colspan="1" rowspan="1">635 (90.2%)</td>
<td align="center" colspan="1" rowspan="1">196 (92.9%)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hx of MI</td>
<td align="center" colspan="1" rowspan="1">122 (43.0%)</td>
<td align="center" colspan="1" rowspan="1">414 (58.8%)</td>
<td align="center" colspan="1" rowspan="1">157 (74.4%)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prior PCI</td>
<td align="center" colspan="1" rowspan="1">52 (24.3%)</td>
<td align="center" colspan="1" rowspan="1">242 (46.9%)</td>
<td align="center" colspan="1" rowspan="1">62 (42.5%)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prior CABG</td>
<td align="center" colspan="1" rowspan="1">42 (19.6%)</td>
<td align="center" colspan="1" rowspan="1">134 (26.0%)</td>
<td align="center" colspan="1" rowspan="1">54 (37.0%)</td>
<td align="center" colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hx of cerebrovascular disease</td>
<td align="center" colspan="1" rowspan="1">61 (21.5%)</td>
<td align="center" colspan="1" rowspan="1">118 (16.8%)</td>
<td align="center" colspan="1" rowspan="1">25 (11.8%)</td>
<td align="center" colspan="1" rowspan="1">0.02</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hx of peripheral arterial disease</td>
<td align="center" colspan="1" rowspan="1">58 (20.4%)</td>
<td align="center" colspan="1" rowspan="1">105 (14.9%)</td>
<td align="center" colspan="1" rowspan="1">37 (17.5%)</td>
<td align="center" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypertension</td>
<td align="center" colspan="1" rowspan="1">266 (93.7%)</td>
<td align="center" colspan="1" rowspan="1">661 (93.9%)</td>
<td align="center" colspan="1" rowspan="1">188 (89.1%)</td>
<td align="center" colspan="1" rowspan="1">0.05</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hyperlipidemia</td>
<td align="center" colspan="1" rowspan="1">208 (73.2%)</td>
<td align="center" colspan="1" rowspan="1">614 (87.2%)</td>
<td align="center" colspan="1" rowspan="1">175 (82.9%)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Duration of diabetes at BL</td>
<td align="center" colspan="1" rowspan="1">13.00 (9.3)</td>
<td align="center" colspan="1" rowspan="1">12.67 (8.2)</td>
<td align="center" colspan="1" rowspan="1">12.45 (8.5)</td>
<td align="center" colspan="1" rowspan="1">0.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Depression</td>
<td align="center" colspan="1" rowspan="1">10 (4.7%)</td>
<td align="center" colspan="1" rowspan="1">44 (8.5%)</td>
<td align="center" colspan="1" rowspan="1">23 (15.8%)</td>
<td align="center" colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Select HF medications at BL*</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Angiotensin-converting enzyme inhibitor</td>
<td align="center" colspan="1" rowspan="1">171 (60.2%)</td>
<td align="center" colspan="1" rowspan="1">443 (62.9%)</td>
<td align="center" colspan="1" rowspan="1">134 (63.5%)</td>
<td align="center" colspan="1" rowspan="1">0.68</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Angiotensin receptor blocker</td>
<td align="center" colspan="1" rowspan="1">83 (29.2%)</td>
<td align="center" colspan="1" rowspan="1">176 (25.0%)</td>
<td align="center" colspan="1" rowspan="1">53 (25.1%)</td>
<td align="center" colspan="1" rowspan="1">0.37</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Beta blocker</td>
<td align="center" colspan="1" rowspan="1">191 (67.3%)</td>
<td align="center" colspan="1" rowspan="1">563 (80.0%)</td>
<td align="center" colspan="1" rowspan="1">187 (88.6%)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aldosterone antagonist</td>
<td align="center" colspan="1" rowspan="1">21 (7.4%)</td>
<td align="center" colspan="1" rowspan="1">94 (13.4%)</td>
<td align="center" colspan="1" rowspan="1">62 (29.4%)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diuretic</td>
<td align="center" colspan="1" rowspan="1">164 (57.7%)</td>
<td align="center" colspan="1" rowspan="1">392 (55.7%)</td>
<td align="center" colspan="1" rowspan="1">149 (70.6%)</td>
<td align="center" colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Body mass index (mean [SD])</td>
<td align="center" colspan="1" rowspan="1">33.9 (6.7)</td>
<td align="center" colspan="1" rowspan="1">34.1 (6.5)</td>
<td align="center" colspan="1" rowspan="1">32.9 (6.5)</td>
<td align="center" colspan="1" rowspan="1">0.055</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Systolic BP (mean [SD])</td>
<td align="center" colspan="1" rowspan="1">136.6 (15.4)</td>
<td align="center" colspan="1" rowspan="1">135.2 (15.0)</td>
<td align="center" colspan="1" rowspan="1">128.4 (17.0)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diastolic BP (mean [SD])</td>
<td align="center" colspan="1" rowspan="1">79.8 (9.7)</td>
<td align="center" colspan="1" rowspan="1">77.8 (10.3)</td>
<td align="center" colspan="1" rowspan="1">75.8 (10.8)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NT-proBNP**</td>
<td align="center" colspan="1" rowspan="1">188.8 [89.7, 384.5]</td>
<td align="center" colspan="1" rowspan="1">206.8 [94.9, 442.5]</td>
<td align="center" colspan="1" rowspan="1">546.3 [262.0, 1254.8]</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HbA1c (%) (mean [SD])</td>
<td align="center" colspan="1" rowspan="1">8.3 (1.0)</td>
<td align="center" colspan="1" rowspan="1">8.1 (1.0)</td>
<td align="center" colspan="1" rowspan="1">8.2 (1.0)</td>
<td align="center" colspan="1" rowspan="1">0.05</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Creatinine (mg/dl) (mean [SD])</td>
<td align="center" colspan="1" rowspan="1">1.0 (0.3)</td>
<td align="center" colspan="1" rowspan="1">1.0 (0.3)</td>
<td align="center" colspan="1" rowspan="1">1.2 (0.3)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">eGFR (mean [SD])</td>
<td align="center" colspan="1" rowspan="1">76.8 (20.5)</td>
<td align="center" colspan="1" rowspan="1">79.2 (20.7)</td>
<td align="center" colspan="1" rowspan="1">72.1 (21.9)</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p15">
<p>Values are reported as mean (SD) or n (%)</p>
<p>*Data on angiotensin receptor-neprilysin inhibitor utilization not available; data on sodium-glucose cotransporter-2 inhibitor available in a minority of participants â€“ see Supplement</p>
<p>**Clinical NT-proBNP values available at baseline in 865/1199 participants; median [IQR] presented given values are skewed</p>
</div></div></section></section><section id="Sec8"><h3 class="pmc_sec_title">Protein dimensionality reduction and association between protein factors with EF groups</h3>
<p id="Par18">PCA with varimax rotation of <em>N</em>â€‰=â€‰4979 proteins resulted in 625 protein factors; 128 factors had multiple heavily loaded proteins and 497 factors had a single protein heavily loaded on the factor (Supplemental Table <a href="#MOESM2" class="usa-link">4</a>). These PCA factors explain 80.3% of the variance in the data. Scree plot included as Supplemental Fig.Â <a href="#MOESM2" class="usa-link">2</a>. PC-PC plots color-coded by plate run dates (split into three plots for ease of visualization) demonstrated no batch effects detected in our samples (Supplemental Fig.Â <a href="#MOESM2" class="usa-link">3</a>). Factors heavily loaded with a single protein were analyzed as individual proteins (i.e. unweighted). In discovery analyses across all protein factors/proteins, ANOVA (FDR adjusted for multiple comparisons considering 625 comparisons) across the three EF groups identified 24 PCA protein factors that were significantly different (FDRâ€‰&lt;â€‰0.1) across EF groups, of which 16 were heavily loaded with only one protein and thus analyzed as individual proteins (TableÂ <a href="#Tab2" class="usa-link">2</a>). The PCA protein factors with multiple loaded proteins were comprised of 261 (factor 4), 12 (factor 37), 7 (factor 38), 14 (factor 67), 4 (factor 78), 6 (factor 108), 2 (factor 149), and 2 (factor 381) heavily loaded proteins respectively. Of note, NT-proBNP was loaded on factor 381 (factor loading 0.488).</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Factors/proteins significantly associated with EF group by FDR-adjusted ANOVA across the three EF groups.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Factors</th>
<th align="left" colspan="1" rowspan="1">Heavily loaded proteins</th>
<th align="left" colspan="1" rowspan="1">pval.anova</th>
<th align="left" colspan="1" rowspan="1">qval.anova</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 4</td>
<td align="left" colspan="1" rowspan="1">SAP3, DAN, Cystatin C</td>
<td align="left" colspan="1" rowspan="1">9.03Eâˆ’11</td>
<td align="left" colspan="1" rowspan="1">5.64Eâˆ’08</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 381</td>
<td align="left" colspan="1" rowspan="1">BNP, NT-proBNP</td>
<td align="left" colspan="1" rowspan="1">7.00Eâˆ’10</td>
<td align="left" colspan="1" rowspan="1">2.19Eâˆ’07</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 113*</td>
<td align="left" colspan="1" rowspan="1">Angiotensinogen</td>
<td align="left" colspan="1" rowspan="1">9.95Eâˆ’06</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 108</td>
<td align="left" colspan="1" rowspan="1">Tenascin, ELA1</td>
<td align="left" colspan="1" rowspan="1">9.57Eâˆ’06</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 38</td>
<td align="left" colspan="1" rowspan="1">MMP-9, Prokineticin-2, CRLD2</td>
<td align="left" colspan="1" rowspan="1">4.67Eâˆ’05</td>
<td align="left" colspan="1" rowspan="1">0.006</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 256*</td>
<td align="left" colspan="1" rowspan="1">CD320</td>
<td align="left" colspan="1" rowspan="1">0.0003</td>
<td align="left" colspan="1" rowspan="1">0.027</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 613*</td>
<td align="left" colspan="1" rowspan="1">IGF-II receptor</td>
<td align="left" colspan="1" rowspan="1">0.0005</td>
<td align="left" colspan="1" rowspan="1">0.036</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 382*</td>
<td align="left" colspan="1" rowspan="1">DRGX</td>
<td align="left" colspan="1" rowspan="1">0.0004</td>
<td align="left" colspan="1" rowspan="1">0.036</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 432*</td>
<td align="left" colspan="1" rowspan="1">sRAGE</td>
<td align="left" colspan="1" rowspan="1">0.0007</td>
<td align="left" colspan="1" rowspan="1">0.04</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 599*</td>
<td align="left" colspan="1" rowspan="1">PGFRL</td>
<td align="left" colspan="1" rowspan="1">0.0007</td>
<td align="left" colspan="1" rowspan="1">0.04</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 149</td>
<td align="left" colspan="1" rowspan="1">sICAM-5</td>
<td align="left" colspan="1" rowspan="1">0.0006</td>
<td align="left" colspan="1" rowspan="1">0.04</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 339*</td>
<td align="left" colspan="1" rowspan="1">HGFA</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 650*</td>
<td align="left" colspan="1" rowspan="1">SIA7E</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 78</td>
<td align="left" colspan="1" rowspan="1">IgM, PCDA4, Calpastatin</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 435*</td>
<td align="left" colspan="1" rowspan="1">TKN1</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 37</td>
<td align="left" colspan="1" rowspan="1">Trypsin, carboxypeptidase B1, LIPP</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 408*</td>
<td align="left" colspan="1" rowspan="1">NOVA1</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
<td align="left" colspan="1" rowspan="1">0.08</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 606*</td>
<td align="left" colspan="1" rowspan="1">MIP-5</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
<td align="left" colspan="1" rowspan="1">0.08</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 15*</td>
<td align="left" colspan="1" rowspan="1">OBP2B</td>
<td align="left" colspan="1" rowspan="1">0.002</td>
<td align="left" colspan="1" rowspan="1">0.08</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 595*</td>
<td align="left" colspan="1" rowspan="1">SCAM5</td>
<td align="left" colspan="1" rowspan="1">0.003</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 451*</td>
<td align="left" colspan="1" rowspan="1">CASQ2</td>
<td align="left" colspan="1" rowspan="1">0.003</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 358*</td>
<td align="left" colspan="1" rowspan="1">ADA19</td>
<td align="left" colspan="1" rowspan="1">0.003</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 341*</td>
<td align="left" colspan="1" rowspan="1">CBLN1</td>
<td align="left" colspan="1" rowspan="1">0.003</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Factor 67</td>
<td align="left" colspan="1" rowspan="1">TOIP1, CADH7, COX6C</td>
<td align="left" colspan="1" rowspan="1">0.004</td>
<td align="left" colspan="1" rowspan="1">0.10</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p22"><p>*Factors with one heavily loaded protein</p></div></div></section><p id="Par19">In analyses of individual proteins most heavily loaded on these PCA protein factors, 293 individual proteins remained significantly associated with EF groups. The majority of these proteins (<em>n</em>â€‰=â€‰270, 92%) remained significant in multivariable models with strongest results for NTpro-BNP (individual protein nominal <em>p</em>-value 4.16e-26), BNP, cystatin-C, and collagen alpha-1 (XXVIII) chain (COL28A1).</p></section><section id="Sec9"><h3 class="pmc_sec_title">Protein patterns across EF groups</h3>
<p id="Par21">Patterns across EF groups were defined based on nominal significance (<em>p</em>â€‰&lt;â€‰0.05) of multivariable pairwise comparisons between groups. As above, 270 individual proteins from PCA factors remained significantly different across EF groups in multivariable models. The majority (236, 87%) of these proteins were differentially higher in one EF group (with the other two groups not having different levels), while eight (3%) of these proteins demonstrated a graded increasing pattern across declining EF groups.</p>
<p id="Par22">The dominant pattern across groups was of higher levels of proteins in HFrEF as compared to both HFmrEF and HFpEF, with similar protein levels in HFmrEF as compared with HFpEF (<em>n</em>â€‰=â€‰203 proteins, 75.2%; Figs.Â <a href="#Fig1" class="usa-link">1</a> and <a href="#Fig2" class="usa-link">2</a>, Supplemental Fig.Â <a href="#MOESM2" class="usa-link">4</a>). This pattern included previously established biomarkers of troponin T and cystatin-C, as well as proteins residing in multiple biologic domains including extracellular matrix/space regulation (e.g. COL28A1, TNC), angiogenesis (e.g. VEGFa, VEGFd), humoral immune response (e.g. B2M), inflammation (e.g. TNF ligands/receptors), and growth factor response/regulation (e.g. IGFBPs). Eight proteins (3% of all proteins, including MMP-9, cysteine-rich secretory protein LCCL domain-containing 2, and prokineticin-2) demonstrated a pattern with significantly different levels in HFpEF as compared with both HFrEF and HFmrEF (with non-different levels in HFrEF vs. HFmrEF; Supplemental Fig.Â <a href="#MOESM2" class="usa-link">5</a>). Eight proteins (3%, including selenoprotein W, CD48 antigen, programmed cell death 1 ligand 2) demonstrated a pattern with lower levels in HFmrEF compared to both other groups (Supplemental Fig.Â <a href="#MOESM2" class="usa-link">6</a>). Eight proteins (3%) showed a steadily increasing pattern of protein levels across declining EF groups (i.e. higher levels in HFrEF, intermediate in HFmrEF and lowest in HFpEF) including NTpro-BNP, hepatitis A virus cellular receptor 2 (TIMD3), neutrophil gelatinase-associated lipocalin (lipocalin 2), and hepatocyte growth factor (Supplemental Fig.Â <a href="#MOESM2" class="usa-link">7</a>).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361379_41598_2025_14414_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa6/12361379/bdfa09733607/41598_2025_14414_Fig1_HTML.jpg" loading="lazy" id="d33e1324" height="316" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Study flowchart and key findings.</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361379_41598_2025_14414_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa6/12361379/37f3a6010d45/41598_2025_14414_Fig2_HTML.jpg" loading="lazy" id="d33e1334" height="1124" width="666" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Heatmap of mean protein levels significantly different across HF groups.</p></figcaption></figure></section><section id="Sec10"><h3 class="pmc_sec_title">Biologic pathways across EF groups</h3>
<p id="Par25">To further understand the biologic pathways represented by these proteins, overrepresentation analyses (ORA) were performed with significant individual proteins, which revealed several pathways (TableÂ <a href="#Tab3" class="usa-link">3</a>) to be significantly enriched among proteins with similar levels between HFmrEF and HFpEF (translating to 766 of 4755 genes, all with nominal <em>p</em>â€‰&lt;â€‰0.05) including pathways of epithelial-mesenchymal transition (nominal <em>p</em>â€‰&lt;â€‰0.001, 38 genes including those associated with IGF binding proteins, TNC, TNF receptors, and VEGFa), ECM receptor interaction, complement and coagulation cascades, cell adhesion molecules, and TGF beta signaling. ORA demonstrated fewer pathways (Supplemental Table <a href="#MOESM2" class="usa-link">5</a>) to be significantly enriched among proteins with similar expression levels between HFmrEF and HFrEF (120 among 4755 genes, all with nominal <em>p</em>â€‰&lt;â€‰0.05). These pathways included hematopoietic cell lineage, dilated cardiomyopathy, and ECM receptor interaction.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Overrepresentation analysis for proteins with similar levels in HFmrEF-HFpEF.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">Pathway size</th>
<th align="left" colspan="1" rowspan="1">Significant genes in pathway</th>
<th align="left" colspan="1" rowspan="1">Nominal <em>p</em>-value</th>
<th align="left" colspan="1" rowspan="1">Select genes</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Epithelial-mesenchymal transition (EMT)</td>
<td align="center" colspan="1" rowspan="1">143</td>
<td align="center" colspan="1" rowspan="1">38</td>
<td align="center" colspan="1" rowspan="1">&lt;â€‰0.001</td>
<td align="left" colspan="1" rowspan="1">IGFBPs, TNC, VEGFa</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cell adhesion molecules (CAMs)</td>
<td align="center" colspan="1" rowspan="1">70</td>
<td align="center" colspan="1" rowspan="1">18</td>
<td align="center" colspan="1" rowspan="1">0.02</td>
<td align="left" colspan="1" rowspan="1">CADMs, CD8a</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Complement and coagulation cascades</td>
<td align="center" colspan="1" rowspan="1">60</td>
<td align="center" colspan="1" rowspan="1">18</td>
<td align="center" colspan="1" rowspan="1">0.003</td>
<td align="left" colspan="1" rowspan="1">CD46, CD55</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extracellular matrix receptor interaction</td>
<td align="center" colspan="1" rowspan="1">47</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">0.048</td>
<td align="left" colspan="1" rowspan="1">COL6A2, TNC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Apical surface</td>
<td align="center" colspan="1" rowspan="1">23</td>
<td align="center" colspan="1" rowspan="1">9</td>
<td align="center" colspan="1" rowspan="1">0.005</td>
<td align="left" colspan="1" rowspan="1">CD160, IL2RB</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Apical junction</td>
<td align="center" colspan="1" rowspan="1">108</td>
<td align="center" colspan="1" rowspan="1">24</td>
<td align="center" colspan="1" rowspan="1">0.04</td>
<td align="left" colspan="1" rowspan="1">EGFR, ICAMs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hedgehog signaling</td>
<td align="center" colspan="1" rowspan="1">20</td>
<td align="center" colspan="1" rowspan="1">7</td>
<td align="center" colspan="1" rowspan="1">0.03</td>
<td align="left" colspan="1" rowspan="1">BMPs, GAS1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pancreas beta cells</td>
<td align="center" colspan="1" rowspan="1">18</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="center" colspan="1" rowspan="1">0.046</td>
<td align="left" colspan="1" rowspan="1">GCK, PCSKs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TGF beta signaling</td>
<td align="center" colspan="1" rowspan="1">54</td>
<td align="center" colspan="1" rowspan="1">14</td>
<td align="center" colspan="1" rowspan="1">0.03</td>
<td align="left" colspan="1" rowspan="1">BMPs, INHBs</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec11"><h3 class="pmc_sec_title">Association between identified proteins and incident hHF</h3>
<p id="Par27">HF hospitalization and mortality event rates were higher in participants with HFrEF, but substantial across all EF groups (Supplemental Table <a href="#MOESM2" class="usa-link">3</a>). Baseline levels of the majority of individual proteins significantly associated with EF group also demonstrated association with time-to-incident hHF in multivariable analysis (92% of 270 proteins, all fdr <em>p</em>-valueâ€‰&lt;â€‰0.05; Fig.Â <a href="#Fig3" class="usa-link">3</a>). As expected, NT-proBNP levels at baseline were associated with time-to-incident hHF (NT-proBNP, multivariable HR [aHR] 3.13 [95% CI: 2.68â€“3.67], <em>p</em>â€‰&lt;â€‰0.0001). Other proteins demonstrated strong effects including COL28A1 (aHR 13.99 [95% CI 8.90-21.99], nominal <em>p</em>â€‰&lt;â€‰0.0001), cystatin-C (aHR 13.54 [95% CI: 8.25â€“22.22], <em>p</em>â€‰&lt;â€‰0.0001), TNC [aHR 8.61 [95% CI: 5.39â€“13.75], <em>p</em>â€‰&lt;â€‰0.0001), tumor necrosis factor receptor superfamily member 1Â A (aHR 6.54 [95% CI: 4.31â€“9.94], <em>p</em>â€‰&lt;â€‰0.0001), and NT-proBNP (aHR 3.13 [95% CI: 2.68â€“3.67], <em>p</em>â€‰&lt;â€‰0.0001). Notably, each of these proteins had demonstrated a pattern of higher levels in HFrEF and similar levels in HFmrEF/HFpEF, except for NTpro-BNP, which after multivariable adjustment, showed a graded increasing pattern across the three EF groups. Results after scaling protein levels demonstrated the same 249 significant proteins with variations in exact hazard ratios and confidence intervals (Supplemental Fig.Â <a href="#MOESM2" class="usa-link">8</a>).</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361379_41598_2025_14414_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa6/12361379/0cff0de50bb2/41598_2025_14414_Fig3_HTML.jpg" loading="lazy" id="d33e1527" height="447" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Volcano plot of results of multivariable Cox proportional hazards models for association between baseline protein expression and time-to-incident heart failure hospitalization (hHF).</p></figcaption></figure><p id="Par29">Given the potential clinical utility of understanding how changes in these biologic pathways may presage HF development, we then examined whether change in protein levels from baseline to 12Â months was associated with time-to-incident hHF. Twenty four proteins were associated with time-to-incident hHF (i.e. events after 12-month follow-up) including NT-proBNP (multivariable HR 1.85 [1.37â€“2.51], <em>p</em>â€‰=â€‰0.005), transmembrane emp24 domain-containing protein 10 (TMED10, HR 5.64 [2.46â€“12.93], <em>p</em>â€‰=â€‰0.004), TNC (HR 5.82 [3.09â€“10.95], <em>p</em>â€‰&lt;â€‰0.001), and epidermal growth factor receptor (HR 0.02 [0.003â€“0.12], <em>p</em>â€‰=â€‰0.003) (Fig.Â <a href="#Fig4" class="usa-link">4</a>). Seventeen proteins (including NT-proBNP, BNP, transmembrane emp24 domain-containing protein 10, matrilin-2, and TNC) demonstrated higher risk with an increase in mean protein levels, with the other proteins showing higher risk with a decrease in mean protein levels (Supplemental Figs.Â <a href="#MOESM2" class="usa-link">9</a> and <a href="#MOESM2" class="usa-link">10</a>). Results after scaling protein levels demonstrated the same 24 significant proteins with variations in exact hazard ratios and confidence intervals (Supplemental Fig.Â <a href="#MOESM2" class="usa-link">11</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361379_41598_2025_14414_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa6/12361379/9ac4e0d130fb/41598_2025_14414_Fig4_HTML.jpg" loading="lazy" id="d33e1564" height="449" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Volcano plot of results of multivariable Cox proportional hazards models for association between change in protein expression over 12Â months and time-to-incident heart failure hospitalization hHF).</p></figcaption></figure></section><section id="Sec12"><h3 class="pmc_sec_title">Change in protein levels with GLP-1 RA therapy</h3>
<p id="Par31">To understand whether the proteins we identified that differentiate EF groups are modified by EQW therapy, we then conducted linear mixed models and evaluation of interaction between treatment and timepoint on protein levels. Levels of 111 (41%) of proteins changed from baseline to 12Â months differentially by EQW treatment as compared with placebo (nominal interaction <em>p</em>â€‰&lt;â€‰0.05, Fig.Â <a href="#Fig5" class="usa-link">5</a>). The majority (84/111, 76%) of these proteins increased to a greater degree in the EQW arm as compared with placebo. The minority (27/111, 24%) of these proteins were reduced to a greater degree in the EQW arm as compared with placebo; baseline levels of 26 of these proteins were associated with higher risk of hHF (including TNC and NT-proBNP). These results suggest that these 26 proteins reporting at baseline on higher risk of incident hHF are beneficially modified by EQW therapy. TNC had also demonstrated an increased risk for hHF with increase in protein level from baseline to 12Â months.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12361379_41598_2025_14414_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa6/12361379/d061f82cd1b4/41598_2025_14414_Fig5_HTML.jpg" loading="lazy" id="d33e1584" height="1182" width="628" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Select plots of interaction between treatment vs. placebo and change in protein (baseline to 12 month). *Results from multiple Somamer reagents targeting different epitopes of theTenascin-C protein are included here.</p></figcaption></figure></section><section id="Sec13"><h3 class="pmc_sec_title">Results summary across analyses</h3>
<p id="Par33">In summary, across our multiple analyses, several proteins were identified as (1) differentially expressed across LVEF HF subtypes, (2) associated with incident hHF (either as baseline protein levels, change in levels, or both), and (3) modified by the glucagon-like peptide receptor agonist (GLP-1 RA), exenatide. These included NT-proBNP, TNC, TMED10, EGFR, TPPP2, CgA, HSPB6, and MATN2.</p></section></section><section id="Sec14"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par34">In this multinational, carefully adjudicated clinical trial cohort, we report herein the largest and most comprehensive proteomics analysis of HF across EF. Specifically, we find that the majority of protein levels measured were similar between HFmrEF and HFpEF. Biologic pathways represented by these proteins highlight the role of extracellular matrix regulation, angiogenesis, inflammation, and epithelial-mesenchymal transition. We also find that the majority of proteins reporting on differences in EF were also associated with incident hHF and many appear to be beneficially modified by the GLP-1 RA exenatide. These protein patterns and associations are hypothesis-generating for potential pharmacologic targets for the management of HF and concomitant T2DM. These findings suggest that HFmrEF may be more biologically similar to HFpEF and suggest that clinical and outcome differences seen in some prior secondary/subset and registry studies of HFmrEF<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>â€“<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup> may not be related to underlying biologic differences.</p>
<p id="Par35">This dominant pattern across EF groups (similar protein levels in HFmrEF and HFpEF) was driven primarily by proteins with higher mean levels in individuals with HFrEF, including established biomarkers such as troponin T and cystatin-C; NT-proBNP was also higher in HFrEF but with a graded increase across EF as discussed below. The majority of these proteins were also prognostic for incident hHF, and several were pharmacologically significantly modified by EQW (including troponin T and NT-proBNP). Further, overrepresentation analyses revealed several pathways to be significantly enriched among proteins with different levels in HFrEF and similar levels between HFmrEF and HFpEF including pathways of epithelial-mesenchymal transition (EMT, including genes associated with IGF binding proteins, TNC, TNF receptors, and VEGFa), ECM receptor interaction, complement and coagulation cascades, cell adhesion molecules, and TGF beta signaling.</p>
<p id="Par36">Notably, the pathophysiologic domain of EMT, the top pathway in the overrepresentation analysis, was overexpressed in this pattern in alignment with prior HF studies in animal and translational models<sup><a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>â€“<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup> and smaller human proteomics studies<sup><a href="#CR39" class="usa-link" aria-describedby="CR39">39</a></sup>. This underscores its potential role in HF for the first time to our knowledge in a large, clinical cohort of human patients with HF. Tenascin C, a key extracellular matrix protein that plays a role in EMT among other processes, demonstrated this expression pattern in HFrEF compared to HFmrEF/HFpEF. Tenascin C has known pleiotropic effects but appears to primarily act as a proinflammatory and profibrotic modulator in HF, thereby worsening adverse myocardial remodeling<sup><a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>â€“<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a></sup>, and has been shown to be elevated in both HFrEF and HFpEF<sup><a href="#CR43" class="usa-link" aria-describedby="CR43">43</a></sup>. In this study, both baseline level and change in tenascin C predicted HF hospitalization and changed beneficially with EQW, demonstrating a robust profile of prognostic and modifiable biomarker that varies by EF. Interestingly, epidermal growth factor receptor (EGFR) demonstrated the opposite of this dominant pattern (i.e. higher mean levels in individuals with HFpEF or HFmrEF, as compared with HFrEF). This is consistent with one of the primary findings from one of the few other smaller studies comparing plasma proteome of HFpEF vs. ischemic HFrEF<sup><a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup>. Lower baseline levels and a decrease from baseline to 12 months in EGFR levels were also associated with higher risk of incident hHF and EGFR levels were modified by EQW therapy (but in a potentially unfavorable direction, i.e. decreased in intervention arm). These data support further investigation into the role of EGFs and EGFRs in heart failure, a pathophysiologic phenomenon that appears complex and incompletely understood to date. While a degree of EGF/EGFR activity is normal for cardiac development and functioning<sup><a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>,<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a></sup>, overexpression of EGF may be associated with CV disease, atrial fibrillation, and HF<sup><a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>â€“<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a></sup>. Further, EGFR overexpression in mouse models may promote HOCM-like phenotypes with regression of this phenotype by EGFR inhibition<sup><a href="#CR47" class="usa-link" aria-describedby="CR47">47</a></sup>. On the other hand, blocking EGFR signaling with tyrosine kinase inhibition in humans is associated with development of HF in rare cases<sup><a href="#CR48" class="usa-link" aria-describedby="CR48">48</a></sup>. Findings from the present study are unable to determine causality or fully elucidate the role of EGFR signaling, but support the prognostic role of EGFR in patients with HF, particularly those with HFmrEF/HFpEF.</p>
<p id="Par37">Other protein patterns across LVEF categories were uncommon (&lt;â€‰3% each), including the pattern of graded progression across EF groups with significant differences between HFrEF, HFmrEF, and HFpEF. This included the established biomarker, NTpro-BNP, as well as proteins of immune regulation (hepatitis A virus cellular receptor 2) and those reflecting renal injury (e.g. neutrophil gelatinase-associated lipocalin, a previously recognized biomarker with mixed evidence in HF<sup><a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>â€“<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a></sup> among others. Properdin was the only protein to demonstrate the relationship of lower levels in HFrEF, which were associated with increased risk for adverse outcomes (consistent with prior studies)<sup><a href="#CR53" class="usa-link" aria-describedby="CR53">53</a></sup>and a graded increase in level as EF increased. All 8 proteins were higher in HFrEF and each of these proteins were also associated with hHF risk, except for trypsin-1 and trypsin-3.</p>
<p id="Par38">Lastly, several proteins (<em>n</em>â€‰=â€‰8) involved in redox homeostasis/antioxidant processes (selenoprotein W) and immune regulation (CD48 antigen, immunoglobulin M, and programmed cell death 1 ligand 2) showed lower expression in HFmrEF compared with HFrEF/HFpEF, and lower levels were associated with lower risk for subsequent hHF from some of these proteins. Additionally, 6 proteins demonstrated significantly higher levels in both HFmrEF and HFrEF compared to HFpEF including prokineticin-2, which was associated with increased hHF risk at higher levels in this study. In addition to its neurologic and gastrointestinal effects, prokineticin-2 has also been shown to play a role in cardiac hypertrophy in hypertensive pressure-overload mice models<sup><a href="#CR54" class="usa-link" aria-describedby="CR54">54</a></sup>. Although prokineticin-2 was not differentially reduced by EQW treatment in this study, this protein pathway may warrant further investigation in HF pathophysiology. Two proteins (calpstatin and ADA19) were elevated in HFpEF as compared to similar levels in HFrEF/HFmrEF, but neither was associated with incident hHF.</p>
<p id="Par39">This study also adds to the growing literature describing biologic mechanisms leading to the development and progression of HF. These previous studies have identified dominant biologic domains with considerable overlap to the present study including the domains of inflammation/apoptosis, growth factor binding, and extracellular matrix remodeling (and related angiogenesis processes)<sup><a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>,<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>â€“<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a></sup>. Further, this analysis extends and builds upon findings from similar prior, smaller studies studying the biology of the EF spectrum<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>â€“<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>,<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>,<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>,<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>,<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a></sup>. A few early studies suggested that HFmrEF may have an intermediate biomarker profile between HFrEF and HFpEF<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>,<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>. For instance, one study demonstrated the top upregulated pathways in HFmrEF were related to neutrophil degranulation, leucocyte migration, and DNA-binding transcription factor activity, and this was intermediate between the dominant biological pathways of HFrEF and HFpEF<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>. Another study found only BNP, KIM-1, RBC, and Hgb significantly associated with EF and intermediate in HFmrEF<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup>. These analyses had several limitations including being based on a relatively small number of proteins (&lt;â€‰100)<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>,<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>.</p>
<p id="Par40">Consistent with our findings, a more recent but smaller study analyzing a smaller number of proteins (<em>n</em>â€‰=â€‰1129 using the SomaLogic platform) in 173 patients found that HFmrEF was more biologically similar to HFpEF, although the degree of this association was affected by whether patients have HFmrEF with recovered EF (i.e. previously HFrEF) or unchanged/stable EF<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>. The analysis noted several differences in biological themes across LVEF groups such as within the domain of â€˜VEGF-A/angiogenesisâ€™ including the proteins angiopoietin-2 and VEGF-A and within the domain of growth factor signaling including insulin-like growth factor-binding proteins. Each of these signals was overexpressed in HFrEF and similar in HFmrEF and HFpEF<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>, which is consistent with our findings. On the other hand, the analysis also noted prominent MMP-activity differentially in HFrEF patients<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>which was not as notable in our study. This analysis also described a few overexpression signals in HFmrEF (complement/opsonization related) and separately in HFpEF (NK-cell markers, VEGF-C/angiogenesis)<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>, which were not noted in our study; still, these signals were fewer than in HFrEF, consistent with our results. Taken together, the findings of our present study and prior analyses suggest that HFmrEF may be a heterogenous biological entity (partly driven by preceding EF trend) but that patients with HFmrEF predominantly demonstrate biological similarities to those with HFpEF.</p>
<p id="Par41">The results of the present analysis also suggest that unique biologic patterns associated with HFmrEF, HFpEF, or HFmrEF/HFpEF (e.g. EFâ€‰&gt;â€‰40%) compared to HFrEF are fairly narrow (18 unique proteins with higher levels). It should be emphasized that this result does not indicate that these biologic processes (e.g. ECM regulation, endothelial function/angiogenesis, inflammation) are not present in HFmrEF/HFpEF compared to non-HF patients; several prior analyses have demonstrated the role of these processes in HFmrEF/HFpEF<sup><a href="#CR60" class="usa-link" aria-describedby="CR60">60</a></sup><sup>âˆ’</sup><sup><a href="#CR64" class="usa-link" aria-describedby="CR64">64</a></sup>. But rather, the present analysis finding indicates these processes (as reflected by systemic protein expression) are more highly expressed in HFrEF as compared to HFmrEF/HFpEF, in patients with concomitant DM. Several factors may explain this finding. First, HFmrEF and HFpEF are heterogenous entities and our analyses likely included HF with recovered EF, low risk early HFpEF, and HF with declining EF (55â€“45%) along with a range of HFpEF phenotypes (which we were not able to differentiate). Second, the HF cohort in this diabetes trial may be distinct from routinely encountered patients with HF; for instance, HFpEF patients are typically older with higher burden of DM compared to patients with HFrEF<sup><a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup> and, in this study, HF patients across EF spectrum were similarly aged and all had DM. Third, residual confounding by factors unadjusted for in the analyses, such as renal function or burden of ischemic vs. non-ischemic cardiomyopathy, may have affected the strength of protein elevations in the HFrEF cohort. Still, it should be noted that the degree of rigor in covariable adjustment is higher in the present study than in previous gold standard studies in this area<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>. Within the context of these possible limitations, this studyâ€™s findings suggest that EF, when applied to a broad chronic HF population, has limited biologic specificity as EF increases above 40% (onlyâ€‰~â€‰0.4% of all proteins studied with unique overexpression in HFmrEF/HFpEF). Taken together, these findings support this movement to expand HF phenotyping and classification beyond EF, particularly when considering patients with EFâ€‰&gt;â€‰40%, to inform development and testing of targeted therapies.</p>
<p id="Par42">Lastly, the results of this analysis also serve as hypothesis-generating findings regarding the molecular effects of contemporary GLP-1 RA. Over 100 proteins changed from baseline to 12Â months differentially with EQW treatment as compared with placebo. Approximately 20 of these proteins were associated with higher risk of hHF <em>and</em> reduced to a greater degree in the EQW arm as compared with placebo; these included NTpro-BNP, TNC, angiopoietin-2, TNFrSF6, and C1q receptor protein, among others. These proteins reflected molecular pathways including myocardial fibrosis/remodeling, myocardial stretch, angiogenesis/endothelial dysfunction, inflammation, apoptosis, and immune regulation, and suggest the benefits of GLP-1 RA therapy may be associated with alterations in these molecular pathways. Further studies are required to determined definitive causal molecular pathways in the effects of GLP-1 RAs and variations in the effects of different modern GLP-1 RAs.</p>
<p id="Par43">Notably, the present study included the largest combination of cohort sample size (<em>n</em>â€‰=â€‰1199 participants) and proteomics panel scale (4979 proteins). Further, to our knowledge, this is the first study to combine this scale of biologic investigation and include prognostication by <em>change in protein</em> levels across three EF groups with additional interaction analyses by treatment (EQW). However, it is important to note several limitations of our study. First, we used EF categorization as collected and documented in the parent EXSCEL trial, which defined a â€˜mid-rangeâ€™ EF as 40â€“55%, since individual level EF results were not available; these EF strata differ slightly from the HF EF categories more recently established since the initiation of the EXSCEL trial, including the category of HFmrEF with EF 41â€“49%<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup>. However, the variability of EF assessment makes it unlikely that such slight changes in EF thresholds would dramatically alter protein patterns evaluated on a large-scale as in this study. Continuous values of ejection fraction and serial values were not available in EXSCEL so we were unable to assess ejection fraction as a continuous variable or sub-categories of HFmrEF/HFpEF (i.e. recovered vs. unchanged); both of these analyses would be valuable in future studies. EXSCEL enrolled participants with DM with a high proportion with prevalent CAD, thus our results may not be generalizable to other populations with HF. Additionally, adjustment variables for our analyses were limited to those collected in the parent trial, which have intrinsic limitations (i.e. definition of BMI alone with regional adiposity metrics) and may be affected by threshold selections (i.e. obesity definition threshold of BMI 30Â kg/m<sup>2</sup>). Finally, we used a broad HF definition; protein differences might be more manifest in a more strictly defined HFmrEF/HFpEF population (i.e. with additional requirements of natriuretic peptide elevation and/or invasively confirmed elevated filling pressures).</p></section><section id="Sec15"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par44">In this large clinical trial, we found that most proteins were similar between HFmrEF and HFpEF and differentially higher in HFrEF in patients with T2DM. These results suggest that HFmrEF may be more biologically similar to HFpEF and highlight novel prognostic and modifiable biomarkers that vary by EF.</p></section><section id="Sec16"><h2 class="pmc_sec_title">Supplementary Information</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12361379/bin/41598_2025_14414_MOESM1_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (286.4KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12361379/bin/41598_2025_14414_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (2.4MB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank the participants of the EXSCEL clinical trial for their participation.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>A.E.P, M.N., and S.H.S developed the project and wrote the main manuscript text. M.N. completed statistical analyses and prepared Figures/Tables. All authors reviewed and revised the initial project concept/plan and then the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>EXSCEL was sponsored and funded by Amylin Pharmaceuticals, Inc., a wholly owned subsidiary of AstraZeneca.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Summary level and deidentifed datasets generated analyzed during the current study are available from thecorresponding author on reasonable request and with approval through established parent clinical trials andcohort study committees.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par45">A.E.P has been supported by the National Heart Lung and Blood Institute (T32HL069749) and has received honoraria from Cytokinetics. J.B.G. receives research support from Merck, Roche and Boehringer Ingelheim/Lilly; honoraria for consulting from Boehringer Ingelheim/Lilly, Novo Nordisk, AstraZeneca, Pfizer, Sanofi, Bayer, Anji, Valo, Vertex, Merck. J.B.B. reports research support from Corcept, Dexcom, and Novo Nordisk; consulting fees from Altimmune, Amgen, ApStem, Aqua Medical, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Dexcom, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Medtronic MiniMed, Mellitus Health, Metsera, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, Vertex, Zealand; stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. H.S. receives research support (to the Medical University of Graz) from Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi and honoraria from AstraZeneca, Amarin, Bayer, Boehringer Ingelheim, Daiichy Sankyo, Eli Lilly, Novo Nordisk and Sanofi. R.R.H. reports personal fees from AstraZeneca, Lilly and Novartis. R.J.M. has received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. S.H.S. receives research support through sponsored research agreements with Lilly Inc., Verily Inc., AstraZeneca Inc. and nference. all other authors have no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisherâ€™s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. <em>Eur. Heart J.</em><strong>42</strong>, 3599â€“3726 (2021).
</cite> [<a href="https://doi.org/10.1093/eurheartj/ehab368" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34447992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McDonagh,%20T.%20A.%20et%20al.%202021%20ESC%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure.%20Eur.%20Heart%20J.42,%203599%E2%80%933726%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. <em>J. Card Fail.</em><strong>28</strong>, e1â€“e167 (2022).</cite> [<a href="https://doi.org/10.1016/j.cardfail.2022.02.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35378257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Heidenreich,%20P.%20A.%20et%20al.%202022%20AHA/ACC/HFSA%20guideline%20for%20the%20management%20of%20heart%20failure.%20J.%20Card%20Fail.28,%20e1%E2%80%93e167%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Putko, B. N. et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology. <em>PLoS One</em>. <strong>9</strong> (2014).</cite> [<a href="https://doi.org/10.1371/journal.pone.0099495" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4055721/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24923671/" class="usa-link">PubMed</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Adamo, L. et al. Proteomic signatures of heart failure in relation to left ventricular ejection fraction. <em>J. Am. Coll. Cardiol.</em><strong>76</strong>, 1982â€“1994 (2020).33092734
</cite> [<a href="https://scholar.google.com/scholar_lookup?Adamo,%20L.%20et%20al.%20Proteomic%20signatures%20of%20heart%20failure%20in%20relation%20to%20left%20ventricular%20ejection%20fraction.%20J.%20Am.%20Coll.%20Cardiol.76,%201982%E2%80%931994%20(2020).33092734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Tromp, J. et al. Biomarker profiles of acute heart failure patients with a Mid-Range ejection fraction. <em>JACC Hear. Fail.</em><strong>5</strong>, 507â€“517 (2017).</cite> [<a href="https://scholar.google.com/scholar_lookup?Tromp,%20J.%20et%20al.%20Biomarker%20profiles%20of%20acute%20heart%20failure%20patients%20with%20a%20Mid-Range%20ejection%20fraction.%20JACC%20Hear.%20Fail.5,%20507%E2%80%93517%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Andrzejczyk, K. et al. Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum. <em>Sci Rep.</em><strong>14</strong>, 1â€“12 (2024). 10.1038/s41598-024-65667-0.</cite> [<a href="https://doi.org/10.1038/s41598-024-65667-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11211454/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38937570/" class="usa-link">PubMed</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Lam, C. S. P. &amp; Solomon, S. D. Fussing over the middle child. <em>Circulation</em><strong>135</strong>, 1279â€“1280 (2017).
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.117.027324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28373521/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lam,%20C.%20S.%20P.%20&amp;%20Solomon,%20S.%20D.%20Fussing%20over%20the%20middle%20child.%20Circulation135,%201279%E2%80%931280%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Solomon, S. D. et al. JJV. Sacubitril/Valsartan across the spectrum of ejection fraction in heart failure. <em>Circulation</em>. 352â€“361 (2020).</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044586" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31736342/" class="usa-link">PubMed</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Solomon, S. D. et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <em>Eur. Heart J.</em><strong>37</strong>, 455â€“462 (2016).
</cite> [<a href="https://doi.org/10.1093/eurheartj/ehv464" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4751235/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26374849/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Solomon,%20S.%20D.%20et%20al.%20Influence%20of%20ejection%20fraction%20on%20outcomes%20and%20efficacy%20of%20spironolactone%20in%20patients%20with%20heart%20failure%20with%20preserved%20ejection%20fraction.%20Eur.%20Heart%20J.37,%20455%E2%80%93462%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Vedin, O. et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: A nationwide cohort study. <em>Circ. Hear. Fail.</em><strong>10</strong>, 1â€“9 (2017).</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28615366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vedin,%20O.%20et%20al.%20Significance%20of%20ischemic%20heart%20disease%20in%20patients%20with%20heart%20failure%20and%20preserved,%20midrange,%20and%20reduced%20ejection%20fraction:%20A%20nationwide%20cohort%20study.%20Circ.%20Hear.%20Fail.10,%201%E2%80%939%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Lund, L. H. et al. Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of Candesartan across the entire ejection fraction spectrum. <em>Eur. J. Heart Fail.</em><strong>20</strong>, 1230â€“1239 (2018).
</cite> [<a href="https://doi.org/10.1002/ejhf.1149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29431256/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lund,%20L.%20H.%20et%20al.%20Heart%20failure%20with%20mid-range%20ejection%20fraction%20in%20CHARM:%20Characteristics,%20outcomes%20and%20effect%20of%20Candesartan%20across%20the%20entire%20ejection%20fraction%20spectrum.%20Eur.%20J.%20Heart%20Fail.20,%201230%E2%80%931239%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Chioncel, O. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC heart failure Long-Term registry. <em>Eur. J. Heart Fail.</em><strong>19</strong>, 1574â€“1585 (2017).
</cite> [<a href="https://doi.org/10.1002/ejhf.813" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28386917/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chioncel,%20O.%20et%20al.%20Epidemiology%20and%20one-year%20outcomes%20in%20patients%20with%20chronic%20heart%20failure%20and%20preserved,%20mid-range%20and%20reduced%20ejection%20fraction:%20An%20analysis%20of%20the%20ESC%20heart%20failure%20Long-Term%20registry.%20Eur.%20J.%20Heart%20Fail.19,%201574%E2%80%931585%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Kumar, V. et al. Incident heart failure with mildly reduced ejection fraction: Frequency, characteristics and outcomes. <em>J Card Fail.</em> (2022).</cite> [<a href="https://doi.org/10.1016/j.cardfail.2022.10.424" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9957946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36332899/" class="usa-link">PubMed</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Tromp, J. et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. <em>J Am. Heart Assoc.</em><strong>6</strong> (2017).</cite> [<a href="https://doi.org/10.1161/JAHA.116.003989" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5532986/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28360225/" class="usa-link">PubMed</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Tromp, J. et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. <em>J. Am. Coll. Cardiol.</em><strong>72</strong>, 1081â€“1090 (2018).
</cite> [<a href="https://doi.org/10.1016/j.jacc.2018.06.050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30165978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tromp,%20J.%20et%20al.%20Identifying%20pathophysiological%20mechanisms%20in%20heart%20failure%20with%20reduced%20versus%20preserved%20ejection%20fraction.%20J.%20Am.%20Coll.%20Cardiol.72,%201081%E2%80%931090%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Konstam, M. A. &amp; Abboud, F. M. Ejection fraction: Mmisunderstood and overrated (Changing the paradigm in categorizing heart Failure). <em>Circulation</em><strong>135</strong>, 717â€“719 (2017).
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.116.025795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5325053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28223323/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Konstam,%20M.%20A.%20&amp;%20Abboud,%20F.%20M.%20Ejection%20fraction:%20Mmisunderstood%20and%20overrated%20(Changing%20the%20paradigm%20in%20categorizing%20heart%20Failure).%20Circulation135,%20717%E2%80%93719%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Greenberg, B., Oâ€™Connor, C. M. &amp; Felker, G. M. Classifying heart failure in the 21st century: Matching taxonomy with science. <em>JACC Hear. Fail.</em><strong>9</strong>, 771â€“773 (2021).</cite> [<a href="https://doi.org/10.1016/j.jchf.2021.08.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34593202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Greenberg,%20B.,%20O%E2%80%99Connor,%20C.%20M.%20&amp;%20Felker,%20G.%20M.%20Classifying%20heart%20failure%20in%20the%2021st%20century:%20Matching%20taxonomy%20with%20science.%20JACC%20Hear.%20Fail.9,%20771%E2%80%93773%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Mann, D. L. Is it time for a new taxonomy for heart failure?? <em>J. Card Fail.</em><strong>22</strong>, 710â€“712 (2016).
</cite> [<a href="https://doi.org/10.1016/j.cardfail.2016.07.432" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27427221/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mann,%20D.%20L.%20Is%20it%20time%20for%20a%20new%20taxonomy%20for%20heart%20failure??%20J.%20Card%20Fail.22,%20710%E2%80%93712%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Holman, R. R. et al. Rationale and design of the exenatide study of cardiovascular event Lowering (EXSCEL) trial. <em>Am. Heart J.</em><strong>174</strong>, 103â€“110 (2016).
</cite> [<a href="https://doi.org/10.1016/j.ahj.2015.12.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26995376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Holman,%20R.%20R.%20et%20al.%20Rationale%20and%20design%20of%20the%20exenatide%20study%20of%20cardiovascular%20event%20Lowering%20(EXSCEL)%20trial.%20Am.%20Heart%20J.174,%20103%E2%80%93110%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Mentz, R. J. et al. Baseline characteristics of patients enrolled in the exenatide study of cardiovascular event Lowering (EXSCEL). <em>Am. Heart J.</em><strong>187</strong>, 1â€“9 (2017).
</cite> [<a href="https://doi.org/10.1016/j.ahj.2017.02.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9849915/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28454792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mentz,%20R.%20J.%20et%20al.%20Baseline%20characteristics%20of%20patients%20enrolled%20in%20the%20exenatide%20study%20of%20cardiovascular%20event%20Lowering%20(EXSCEL).%20Am.%20Heart%20J.187,%201%E2%80%939%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Holman, R. R. et al. Effects of Once-Weekly exenatide on cardiovascular outcomes in type 2 diabetes. <em>N Engl. J. Med.</em><strong>377</strong>, 1228â€“1239 (2017).
</cite> [<a href="https://doi.org/10.1056/NEJMoa1612917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9792409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28910237/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Holman,%20R.%20R.%20et%20al.%20Effects%20of%20Once-Weekly%20exenatide%20on%20cardiovascular%20outcomes%20in%20type%202%20diabetes.%20N%20Engl.%20J.%20Med.377,%201228%E2%80%931239%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Fudim, M. et al. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes. <em>Circulation</em><strong>140</strong>, 1613â€“1622 (2019).
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.041659" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6924268/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31542942/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fudim,%20M.%20et%20al.%20Effect%20of%20once-weekly%20exenatide%20in%20patients%20with%20type%202%20diabetes%20mellitus%20with%20and%20without%20heart%20failure%20and%20heart%20failure-related%20outcomes.%20Circulation140,%201613%E2%80%931622%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Brody, E. et al. Lifeâ€™s simple measures: Unlocking the proteome. <em>J. Mol. Biol.</em><strong>422</strong>, 595â€“606 (2012).
</cite> [<a href="https://doi.org/10.1016/j.jmb.2012.06.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22721953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brody,%20E.%20et%20al.%20Life%E2%80%99s%20simple%20measures:%20Unlocking%20the%20proteome.%20J.%20Mol.%20Biol.422,%20595%E2%80%93606%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Kim, C. H. et al. Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. <em>Sci. Rep.</em><strong>8</strong>, 1â€“10 (2018).
</cite> [<a href="https://doi.org/10.1038/s41598-018-26640-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5976624/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29849057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim,%20C.%20H.%20et%20al.%20Stability%20and%20reproducibility%20of%20proteomic%20profiles%20measured%20with%20an%20aptamer-based%20platform.%20Sci.%20Rep.8,%201%E2%80%9310%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Rohloff, J. C. et al. Nucleic acid ligands with protein-like side chains: Modified aptamers and their use as diagnostic and therapeutic agents. <em>Mol. Ther. Nucleic Acids</em>. <strong>3</strong>, e201 (2014).
</cite> [<a href="https://doi.org/10.1038/mtna.2014.49" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4217074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25291143/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rohloff,%20J.%20C.%20et%20al.%20Nucleic%20acid%20ligands%20with%20protein-like%20side%20chains:%20Modified%20aptamers%20and%20their%20use%20as%20diagnostic%20and%20therapeutic%20agents.%20Mol.%20Ther.%20Nucleic%20Acids.%203,%20e201%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. <em>Sci. (80-)</em>. <strong>361</strong>, 1â€“11 (2018).</cite> [<a href="https://doi.org/10.1126/science.aaq1327" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6190714/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30072576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Emilsson,%20V.%20et%20al.%20Co-regulatory%20networks%20of%20human%20serum%20proteins%20link%20genetics%20to%20disease.%20Sci.%20(80-).%20361,%201%E2%80%9311%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Sun, B. B. et al. Genomic atlas of the human plasma proteome. <em>Nature</em><strong>558</strong>, 73â€“79 (2018).
</cite> [<a href="https://doi.org/10.1038/s41586-018-0175-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6697541/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29875488/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun,%20B.%20B.%20et%20al.%20Genomic%20atlas%20of%20the%20human%20plasma%20proteome.%20Nature558,%2073%E2%80%9379%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. <em>Nat. Med.</em><strong>25</strong>, 1851â€“1857 (2019).
</cite> [<a href="https://doi.org/10.1038/s41591-019-0665-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6922049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31792462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Williams,%20S.%20A.%20et%20al.%20Plasma%20protein%20patterns%20as%20comprehensive%20indicators%20of%20health.%20Nat.%20Med.25,%201851%E2%80%931857%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. &amp; Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. <em>Nucleic Acids Res.</em><strong>53</strong>, D672â€“D677 (2025).
</cite> [<a href="https://doi.org/10.1093/nar/gkae909" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11701520/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39417505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kanehisa,%20M.,%20Furumichi,%20M.,%20Sato,%20Y.,%20Matsuura,%20Y.%20&amp;%20Ishiguro-Watanabe,%20M.%20KEGG:%20Biological%20systems%20database%20as%20a%20model%20of%20the%20real%20world.%20Nucleic%20Acids%20Res.53,%20D672%E2%80%93D677%20(2025)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Chirinos, J. A. et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. <em>J. Am. Coll. Cardiol.</em><strong>75</strong>, 1281â€“1295 (2020).
</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.12.069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7147356/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32192654/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chirinos,%20J.%20A.%20et%20al.%20Multiple%20plasma%20biomarkers%20for%20risk%20stratification%20in%20patients%20with%20heart%20failure%20and%20preserved%20ejection%20fraction.%20J.%20Am.%20Coll.%20Cardiol.75,%201281%E2%80%931295%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Ibrahim, N. E. &amp; Januzzi, J. L. Established and emerging roles of biomarkers in heart failure. <em>Circ. Res.</em><strong>123</strong>, 614â€“629 (2018).
</cite> [<a href="https://doi.org/10.1161/CIRCRESAHA.118.312706" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30355136/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ibrahim,%20N.%20E.%20&amp;%20Januzzi,%20J.%20L.%20Established%20and%20emerging%20roles%20of%20biomarkers%20in%20heart%20failure.%20Circ.%20Res.123,%20614%E2%80%93629%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Dâ€™Elia, E. et al. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: Critical appraisal and practical use. <em>Eur. J. Heart Fail.</em><strong>17</strong>, 1231â€“1239 (2015).
</cite> [<a href="https://doi.org/10.1002/ejhf.430" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26493383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?D%E2%80%99Elia,%20E.%20et%20al.%20Role%20of%20biomarkers%20in%20cardiac%20structure%20phenotyping%20in%20heart%20failure%20with%20preserved%20ejection%20fraction:%20Critical%20appraisal%20and%20practical%20use.%20Eur.%20J.%20Heart%20Fail.17,%201231%E2%80%931239%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Kobayashi, M. et al. Machine Learning-Derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals. <em>JACC Cardiovasc. Imaging</em>. <strong>15</strong>, 193â€“208 (2022).
</cite> [<a href="https://doi.org/10.1016/j.jcmg.2021.07.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34538625/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kobayashi,%20M.%20et%20al.%20Machine%20Learning-Derived%20echocardiographic%20phenotypes%20predict%20heart%20failure%20incidence%20in%20asymptomatic%20individuals.%20JACC%20Cardiovasc.%20Imaging.%2015,%20193%E2%80%93208%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Valero-MunÃµz, M. et al. Endothelial-Mesenchymal transition in heart failure with a preserved ejection fraction: Insights into the cardiorenal syndrome. <em>Circ Hear. Fail</em>. 985â€“997 (2021).</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.121.008372" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8575120/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34407636/" class="usa-link">PubMed</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Wang, B. et al. MFGE8 is down-regulated in cardiac fibrosis and attenuates endothelial-mesenchymal transition through Smad2/3-Snail signalling pathway. <em>J. Cell. Mol. Med.</em><strong>24</strong>, 12799â€“12812 (2020).
</cite> [<a href="https://doi.org/10.1111/jcmm.15871" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7686985/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32945126/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20B.%20et%20al.%20MFGE8%20is%20down-regulated%20in%20cardiac%20fibrosis%20and%20attenuates%20endothelial-mesenchymal%20transition%20through%20Smad2/3-Snail%20signalling%20pathway.%20J.%20Cell.%20Mol.%20Med.24,%2012799%E2%80%9312812%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Wang, G. et al. Role of endothelial and mesenchymal cell transitions in heart failure and recovery thereafter. <em>Front. Genet.</em><strong>11</strong>, 1â€“14 (2021).</cite> [<a href="https://doi.org/10.3389/fgene.2020.609262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7874124/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33584806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20G.%20et%20al.%20Role%20of%20endothelial%20and%20mesenchymal%20cell%20transitions%20in%20heart%20failure%20and%20recovery%20thereafter.%20Front.%20Genet.11,%201%E2%80%9314%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. <em>Nat. Med.</em><strong>13</strong>, 952â€“961 (2007).
</cite> [<a href="https://doi.org/10.1038/nm1613" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17660828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zeisberg,%20E.%20M.%20et%20al.%20Endothelial-to-mesenchymal%20transition%20contributes%20to%20cardiac%20fibrosis.%20Nat.%20Med.13,%20952%E2%80%93961%20(2007)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Fayyaz, A. et al. Histologic and proteomic remodeling of the pulmonary veins and arteries in a Porcine model of chronic pulmonary venous hypertension. <em>Cardiovasc Res.</em> (2022).</cite> [<a href="https://doi.org/10.1093/cvr/cvac005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10233294/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35022664/" class="usa-link">PubMed</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Egerstedt, A. et al. Profiling of the plasma proteome across different stages of human heart failure. <em>Nat. Commun.</em><strong>10</strong>, 1â€“13 (2019).
</cite> [<a href="https://doi.org/10.1038/s41467-019-13306-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6925199/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31862877/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Egerstedt,%20A.%20et%20al.%20Profiling%20of%20the%20plasma%20proteome%20across%20different%20stages%20of%20human%20heart%20failure.%20Nat.%20Commun.10,%201%E2%80%9313%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Imanaka-Yoshida, K., Tawara, I. &amp; Yoshida, T. Tenascin-C in cardiac disease: A sophisticated controller of inflammation, repair, and fibrosis. <em>Am. J. Physiol. - Cell. Physiol.</em><strong>319</strong>, C781â€“C796 (2020).
</cite> [<a href="https://doi.org/10.1152/ajpcell.00353.2020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32845719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Imanaka-Yoshida,%20K.,%20Tawara,%20I.%20&amp;%20Yoshida,%20T.%20Tenascin-C%20in%20cardiac%20disease:%20A%20sophisticated%20controller%20of%20inflammation,%20repair,%20and%20fibrosis.%20Am.%20J.%20Physiol.%20-%20Cell.%20Physiol.319,%20C781%E2%80%93C796%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Sugano, Y. et al. Inhibitory effect of myocardial Tenascin-C against recovery of ejection fraction in patients with Non-Ischemic dilated cardiomyopathy. <em>Circulation</em>. 136. (2018).</cite>
</li>
<li id="CR42">
<span class="label">42.</span><cite>Yokokawa, T. et al. Significance of myocardial tenascin-C expression in left ventricular remodelling and long-term outcome in patients with dilated cardiomyopathy. <em>Eur. J. Heart Fail.</em><strong>18</strong>, 375â€“385 (2016).
</cite> [<a href="https://doi.org/10.1002/ejhf.464" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5066704/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26763891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yokokawa,%20T.%20et%20al.%20Significance%20of%20myocardial%20tenascin-C%20expression%20in%20left%20ventricular%20remodelling%20and%20long-term%20outcome%20in%20patients%20with%20dilated%20cardiomyopathy.%20Eur.%20J.%20Heart%20Fail.18,%20375%E2%80%93385%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Kanagala, P. et al. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. <em>PLoS One</em>. <strong>15</strong>, 1â€“22 (2020).</cite> [<a href="https://doi.org/10.1371/journal.pone.0232280" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7190371/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32349122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kanagala,%20P.%20et%20al.%20Characterizing%20heart%20failure%20with%20preserved%20and%20reduced%20ejection%20fraction:%20An%20imaging%20and%20plasma%20biomarker%20approach.%20PLoS%20One.%2015,%201%E2%80%9322%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Shraim, B. A., Moursi, M. O., Benter, I. F., Habib, A. M. &amp; Akhtar, S. The role of epidermal growth factor receptor family of receptor tyrosine kinases in mediating Diabetes-Induced cardiovascular complications. <em>Front. Pharmacol.</em><strong>12</strong>, 1â€“23 (2021).</cite> [<a href="https://doi.org/10.3389/fphar.2021.701390" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8365470/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34408653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shraim,%20B.%20A.,%20Moursi,%20M.%20O.,%20Benter,%20I.%20F.,%20Habib,%20A.%20M.%20&amp;%20Akhtar,%20S.%20The%20role%20of%20epidermal%20growth%20factor%20receptor%20family%20of%20receptor%20tyrosine%20kinases%20in%20mediating%20Diabetes-Induced%20cardiovascular%20complications.%20Front.%20Pharmacol.12,%201%E2%80%9323%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Makki, N., Thiel, K. W. &amp; Miller, F. J. The epidermal growth factor receptor and its ligands in cardiovascular disease. <em>Int. J. Mol. Sci.</em><strong>14</strong>, 20597â€“20613 (2013).
</cite> [<a href="https://doi.org/10.3390/ijms141020597" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3821633/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24132149/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Makki,%20N.,%20Thiel,%20K.%20W.%20&amp;%20Miller,%20F.%20J.%20The%20epidermal%20growth%20factor%20receptor%20and%20its%20ligands%20in%20cardiovascular%20disease.%20Int.%20J.%20Mol.%20Sci.14,%2020597%E2%80%9320613%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>BÃ¼ttner, P. et al. EGF (Epidermal growth Factor) receptor ligands in atrial fibrillation: From genomic evidence to the identification of new players. <em>Circ Arrhythmia Electrophysiol</em>. <strong>12</strong> (2019).</cite> [<a href="https://doi.org/10.1161/CIRCEP.119.007212" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30894015/" class="usa-link">PubMed</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Sysa-Shah, P. et al. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. <em>PLoS One</em>. <strong>7</strong> (2012).</cite> [<a href="https://doi.org/10.1371/journal.pone.0042805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3415416/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22912742/" class="usa-link">PubMed</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Piper-Vallillo, A. J., Costa, D. B., Sabe, M. A. &amp; Asnani, A. Heart failure associated with the epidermal growth factor receptor inhibitor osimertinib. <em>JACC CardioOncology</em>. <strong>2</strong>, 119â€“122 (2020).
</cite> [<a href="https://doi.org/10.1016/j.jaccao.2020.01.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8352313/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34396216/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Piper-Vallillo,%20A.%20J.,%20Costa,%20D.%20B.,%20Sabe,%20M.%20A.%20&amp;%20Asnani,%20A.%20Heart%20failure%20associated%20with%20the%20epidermal%20growth%20factor%20receptor%20inhibitor%20osimertinib.%20JACC%20CardioOncology.%202,%20119%E2%80%93122%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Yndestad, A. et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated Lipocalin in clinical and experimental heart failure. <em>Eur. Heart J.</em><strong>30</strong>, 1229â€“1236 (2009).
</cite> [<a href="https://doi.org/10.1093/eurheartj/ehp088" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19329498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yndestad,%20A.%20et%20al.%20Increased%20systemic%20and%20myocardial%20expression%20of%20neutrophil%20gelatinase-associated%20Lipocalin%20in%20clinical%20and%20experimental%20heart%20failure.%20Eur.%20Heart%20J.30,%201229%E2%80%931236%20(2009)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Van Deursen, V. M. et al. Prognostic value of plasma neutrophil gelatinase-associated Lipocalin for mortality in patients with heart failure. <em>Circ. Hear. Fail.</em><strong>7</strong>, 35â€“42 (2014).</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.113.000242" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24347663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Van%20Deursen,%20V.%20M.%20et%20al.%20Prognostic%20value%20of%20plasma%20neutrophil%20gelatinase-associated%20Lipocalin%20for%20mortality%20in%20patients%20with%20heart%20failure.%20Circ.%20Hear.%20Fail.7,%2035%E2%80%9342%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Janus, S. E. et al. Multi-variable biomarker approach in identifying incident heart failure in chronic kidney disease: Results from the chronic renal insufficiency cohort study. <em>Eur. J. Heart Fail.</em><strong>24</strong>, 988â€“995 (2022).
</cite> [<a href="https://doi.org/10.1002/ejhf.2543" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35587997/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Janus,%20S.%20E.%20et%20al.%20Multi-variable%20biomarker%20approach%20in%20identifying%20incident%20heart%20failure%20in%20chronic%20kidney%20disease:%20Results%20from%20the%20chronic%20renal%20insufficiency%20cohort%20study.%20Eur.%20J.%20Heart%20Fail.24,%20988%E2%80%93995%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Maisel, A. S. et al. Neutrophil Gelatinase-Associated Lipocalin for acute kidney injury during acute heart failure hospitalizations: The AKINESIS study. <em>J. Am. Coll. Cardiol.</em><strong>68</strong>, 1420â€“1431 (2016).
</cite> [<a href="https://doi.org/10.1016/j.jacc.2016.06.055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27659464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maisel,%20A.%20S.%20et%20al.%20Neutrophil%20Gelatinase-Associated%20Lipocalin%20for%20acute%20kidney%20injury%20during%20acute%20heart%20failure%20hospitalizations:%20The%20AKINESIS%20study.%20J.%20Am.%20Coll.%20Cardiol.68,%201420%E2%80%931431%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Shahini, N. et al. The alternative complement pathway is dysregulated in patients with chronic heart failure. <em>Sci. Rep.</em><strong>7</strong>, 1â€“10 (2017).
</cite> [<a href="https://doi.org/10.1038/srep42532" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5307342/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28195242/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shahini,%20N.%20et%20al.%20The%20alternative%20complement%20pathway%20is%20dysregulated%20in%20patients%20with%20chronic%20heart%20failure.%20Sci.%20Rep.7,%201%E2%80%9310%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Demir, F. et al. Pressure Overload-Mediated sustained PKR2 (Prokineticin-2 Receptor) signaling in cardiomyocytes contributes to cardiac hypertrophy and endotheliopathies. <em>Hypertension</em><strong>77</strong>, 1559â€“1570 (2021).
</cite> [<a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.16808" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33677981/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Demir,%20F.%20et%20al.%20Pressure%20Overload-Mediated%20sustained%20PKR2%20(Prokineticin-2%20Receptor)%20signaling%20in%20cardiomyocytes%20contributes%20to%20cardiac%20hypertrophy%20and%20endotheliopathies.%20Hypertension77,%201559%E2%80%931570%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Ferreira, J. P. et al. Proteomic bioprofiles and mechanistic pathways of progression to heart failure: The HOMAGE study. <em>Circ. Hear. Fail.</em><strong>12</strong>, 1â€“12 (2019).</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.118.005897" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8361846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31104495/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ferreira,%20J.%20P.%20et%20al.%20Proteomic%20bioprofiles%20and%20mechanistic%20pathways%20of%20progression%20to%20heart%20failure:%20The%20HOMAGE%20study.%20Circ.%20Hear.%20Fail.12,%201%E2%80%9312%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Stenemo, M. et al. Circulating proteins as predictors of incident heart failure in the elderly. <em>Eur. J. Heart Fail.</em><strong>20</strong>, 55â€“62 (2018).
</cite> [<a href="https://doi.org/10.1002/ejhf.980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28967680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stenemo,%20M.%20et%20al.%20Circulating%20proteins%20as%20predictors%20of%20incident%20heart%20failure%20in%20the%20elderly.%20Eur.%20J.%20Heart%20Fail.20,%2055%E2%80%9362%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Sanders-Van Wijk, S. et al. Proteomic evaluation of the Comorbidity-Inflammation paradigm in heart failure with preserved ejection fraction: Results from the PROMIS-HFpEF study. <em>Circulation</em>. 2029â€“2044 (2020).</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.120.045810" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7686082/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33034202/" class="usa-link">PubMed</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Regan, J. A., Kwee, L. C., Grass, E., Kraus, W. E. &amp; Shah, S. H. Circulating protein biomarkers associated with heart failure with preserved ejection fraction. <em>J. Card Fail.</em><strong>26</strong>, S2 (2020).</cite> [<a href="https://scholar.google.com/scholar_lookup?Regan,%20J.%20A.,%20Kwee,%20L.%20C.,%20Grass,%20E.,%20Kraus,%20W.%20E.%20&amp;%20Shah,%20S.%20H.%20Circulating%20protein%20biomarkers%20associated%20with%20heart%20failure%20with%20preserved%20ejection%20fraction.%20J.%20Card%20Fail.26,%20S2%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Ferreira, J. P. et al. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. <em>JACC Hear. Fail.</em><strong>9</strong>, 268â€“277 (2021).</cite> [<a href="https://doi.org/10.1016/j.jchf.2020.11.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33549556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ferreira,%20J.%20P.%20et%20al.%20Proteomic%20and%20mechanistic%20analysis%20of%20spironolactone%20in%20patients%20at%20risk%20for%20HF.%20JACC%20Hear.%20Fail.9,%20268%E2%80%93277%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Cunningham, J. W. et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. <em>J. Am. Coll. Cardiol.</em><strong>76</strong>, 503â€“514 (2020).
</cite> [<a href="https://doi.org/10.1016/j.jacc.2020.05.072" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32731928/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cunningham,%20J.%20W.%20et%20al.%20Effect%20of%20sacubitril/valsartan%20on%20biomarkers%20of%20extracellular%20matrix%20regulation%20in%20patients%20with%20HFpEF.%20J.%20Am.%20Coll.%20Cardiol.76,%20503%E2%80%93514%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Franssen, C. &amp; GonzÃ¡lez Miqueo, A. The role of Titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. <em>Neth. Hear. J.</em><strong>24</strong>, 259â€“267 (2016).</cite> [<a href="https://doi.org/10.1007/s12471-016-0812-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4796057/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26886920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Franssen,%20C.%20&amp;%20Gonz%C3%A1lez%20Miqueo,%20A.%20The%20role%20of%20Titin%20and%20extracellular%20matrix%20remodelling%20in%20heart%20failure%20with%20preserved%20ejection%20fraction.%20Neth.%20Hear.%20J.24,%20259%E2%80%93267%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Paulus, W. J. &amp; TschÃ¶pe, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. <em>J. Am. Coll. Cardiol.</em><strong>62</strong>, 263â€“271 (2013).
</cite> [<a href="https://doi.org/10.1016/j.jacc.2013.02.092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23684677/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Paulus,%20W.%20J.%20&amp;%20Tsch%C3%B6pe,%20C.%20A%20novel%20paradigm%20for%20heart%20failure%20with%20preserved%20ejection%20fraction:%20Comorbidities%20drive%20myocardial%20dysfunction%20and%20remodeling%20through%20coronary%20microvascular%20endothelial%20inflammation.%20J.%20Am.%20Coll.%20Cardiol.62,%20263%E2%80%93271%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Cornuault, L., Rouault, P., DuplÃ a, C., Couffinhal, T. &amp; Renault, M. A. Endothelial dysfunction in heart failure with preserved ejection fraction: What are the experimental proofs? <em>Front. Physiol.</em><strong>13</strong>, 1â€“27 (2022).</cite> [<a href="https://doi.org/10.3389/fphys.2022.906272" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9304560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35874523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cornuault,%20L.,%20Rouault,%20P.,%20Dupl%C3%A0a,%20C.,%20Couffinhal,%20T.%20&amp;%20Renault,%20M.%20A.%20Endothelial%20dysfunction%20in%20heart%20failure%20with%20preserved%20ejection%20fraction:%20What%20are%20the%20experimental%20proofs?%20Front.%20Physiol.13,%201%E2%80%9327%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Paulus, W. J. &amp; Zile, M. R. From systemic inflammation to myocardial fibrosis: The heart failure with preserved ejection fraction paradigm revisited. <em>Circ Res.</em>. 1451â€“1467 (2021).</cite> [<a href="https://doi.org/10.1161/CIRCRESAHA.121.318159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8351796/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33983831/" class="usa-link">PubMed</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12361379/bin/41598_2025_14414_MOESM1_ESM.xlsx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (286.4KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12361379/bin/41598_2025_14414_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (2.4MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Summary level and deidentifed datasets generated analyzed during the current study are available from thecorresponding author on reasonable request and with approval through established parent clinical trials andcohort study committees.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Scientific Reports are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41598-025-14414-0"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41598_2025_Article_14414.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.1Â MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12361379/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12361379/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12361379%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12361379/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12361379/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12361379/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40825966/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12361379/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40825966/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12361379/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12361379/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="bc2RxO0oFlzIkPNE9EpQBV8zuAA89rRAiKxiImChhzSvIeA6LGHWoq7op1LCkGzX">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
